TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))						Docket No. PENN0870US.NP	
In Re Application Of: Sweeney et al.							
plica	ation No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
10/566,796		April 2, 2008	Michael V. Meller	26259	1655	8993	
Title: Bowman-Birk Inhibitor Compositions for Treatment of Muscular Atrophy and Degenerative Muscle Disease							
Address to:  Commissioner for Patents  P.O. Box 1450  Alexandria, VA 22313-1450							
37 CFR 1.97(b)							
1. Main The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.							
37 CFR 1.97(c)							
	The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
☐ the statement specified in 37 CFR 1.97(e);							
OR							
☐ the fee set forth in 37 CFR 1.17(p).							
	e Application 10/5	e Application No.  10/566,796  Bowman-Bin  The Inform of a nation three mon application Action after  The Inform CFR 1.97(Final Action otherwise)  the	e Application Of: Sweeney et al.  pplication No. Filing Date 10/566,796 April 2, 2008  Bowman-Birk Inhibitor Composition of a national application other three months of the date of en application; before the mailing Action after the filing of a reque  The Information Disclosure State CFR 1.97(b), provided that the Final Action under 37 CFR 1 otherwise closes prosecution in the statement specified	e Application Of: Sweeney et al.    Sweeney et al.   Sweeney et al.	(Under 37 CFR 1.97(b) or 1.97(c))  e Application Of: Sweeney et al.  pplication No. Filing Date Examiner Customer No. 10/566,796 April 2, 2008 Michael V. Meller 26259  Bowman-Birk Inhibitor Compositions for Treatment of Muscular Atrophy and Date Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450  37 CFR 1.97(b)  The Information Disclosure Statement submitted herewith is being filed within of a national application other than a continued prosecution application und three months of the date of entry of the national stage as set forth in 37 CF application; before the mailing of a first Office Action on the merits, or before Action after the filling of a request for continued examination under 37 CFR 1.  37 CFR 1.97(c)  The Information Disclosure Statement submitted herewith is being filed after CFR 1.97(b), provided that the Information Disclosure Statement is filed be Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR otherwise closes prosecution in the application, and is accompanied by one of the statement specified in 37 CFR 1.97(e);  OR	(Under 37 CFR 1.97(b) or 1.97(c))  e Application Of: Sweeney et al.  pplication No. Filing Date Examiner Customer No. Group Art Unit 10/566,796 April 2, 2008 Michael V. Meller 26259 1655  Bowman-Birk Inhibitor Compositions for Treatment of Muscular Atrophy and Degenerative Musc	

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) PENN0870US.NP In Re Application of: Sweeney et al. Application No. Filing Date Examiner Customer No. Group Art Unit Confirmation No. 10/566,796 **April 2, 2008** Michael V. Meller 26259 8993 1655 Bowman-Birk Inhibitor Compositions for Treatment of Muscular Atrophy and Degenerative Muscle Disease Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. □ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Transmission by Facsimile\* Certificate of Mailing by First Class Mail I certify that this document and authorization to charge deposit I hereby certify that this correspondence is being deposited account is being facsimile transmitted to the United States with the United States Postal Service with sufficient postage Patent and Trademark Office (Fa as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on (Date) (Date) Signature Signature of Person Mailing Correspondence Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate \*This certificate may only be used if paying by deposit account. athleen H Dated: May 3, 2010 Kathleen A. Tyrrell, Esq Registration No. 38,350 Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 US tel: 856-810-1515 fax: 856-810-1454 email: ktyrrell@licataandtyrrell.com CC: